GLYR1 is an epigenetic reader and chr16 regulator that acts as a nucleosome-destabilizing factor recruited during transcriptional activation. It binds histone H3 and DNA without preference for specific epigenetic marks, and forms a multifunctional complex with KDM1B to facilitate histone H3K4 demethylation and promote RNA polymerase II transcription through nucleosomes 1. GLYR1 also stimulates H3K56 acetylation via EP300 and regulates p38 MAPK signaling by promoting MAPK14 phosphorylation and ATF2 activation. During cardiomyocyte differentiation, GLYR1 co-binds cardiac developmental genes with GATA4 to coordinate their expression. In disease contexts, GLYR1 functions as a tumor suppressor. In microsatellite instability colorectal cancer (MSI CRC), GLYR1 downregulation promotes cell cycle progression and reduces sensitivity to 5-fluorouracil via suppressed p38MAPK and activated PI3K/AKT signaling 2. In multiple myeloma, GLYR1 transcriptionally activates PER3 to suppress proliferation and migration 3. Conversely, in breast cancer, GLYR1 represses the tumor-suppressive lncRNA HSD11B1-AS1 to enhance malignant behavior 4. De novo GLYR1 missense variants associate with congenital heart disease through disrupted GATA4 interaction 5. A novel NCOR1::GLYR1 fusion gene was identified in a myelodysplastic/myeloproliferative neoplasm patient who progressed to acute myeloid leukemia. These findings establish GLYR1 as both an epigenetic regulator of transcription and a context-dependent tumor suppressor relevant to hematologic and solid malignancies.